CHIESI FARMACEUTICI S.P.A.

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1935-01-01

Employees: -

Market Cap: -

Website: http://www.chiesigroup.com

Clinical Trials

Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: CHF1535 pMDI + AC Plus
Drug: BDP + AC Plus
Drug: Formoterol + AC Plus

First Posted Date: 2013-05-07

Last Posted Date: 2020-07-31

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 20

Registration Number: NCT01848769

Locations: 🇩🇰
BorneAstmaKlinikken, Copenhagen, Denmark

Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1
Drug: CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).
Drug: BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)
Drug: CHF 1535 100/6 pMDI (Foster®) (CTR)

First Posted Date: 2013-03-04

Last Posted Date: 2020-07-31

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 60

Registration Number: NCT01803087

Locations: 🇵🇱
Uniwersytecki Szpital Kliniczny nr 1, Lodz, Poland

Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder

Phase 2

Completed

Conditions: Asthmatic

Interventions: Drug: NEXThaler 200/6 mcg DPI
Drug: NEXThaler placebo
Drug: NEXThaler 100/6 mcg DPI
Drug: Flixotide Accuhaler 500 mcg

First Posted Date: 2012-11-30

Last Posted Date: 2021-10-29

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 30

Registration Number: NCT01738087

Locations: 🇬🇧
The Medicine Evaluation Unit, Manchester, United Kingdom

Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

Phase 2

Completed

Conditions: COPD

Interventions: Drug: CHF6001 DPI
Drug: Placebo
Drug: Roflumilast

First Posted Date: 2012-11-21

Last Posted Date: 2017-03-29

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 55

Registration Number: NCT01730404

Locations: 🇮🇪
Celerion, Belfast, Ireland
🇬🇧
Medicines Evaluation Unit Ltd, Manchester, United Kingdom
🇬🇧
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

and more 2 locations

Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: CHF 6001 SD or placebo
Drug: CHF 6001 MD or placebo

First Posted Date: 2012-10-10

Last Posted Date: 2020-07-31

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 74

Registration Number: NCT01703052

Locations: 🇬🇧
Quotient Clinical, Nottingham, United Kingdom

beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR Study

Phase 3

Completed

Conditions: Acute Rhinosinusitis

Interventions: Drug: beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days
Drug: placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days

First Posted Date: 2012-09-25

Last Posted Date: 2017-03-29

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 166

Registration Number: NCT01691677

Locations: 🇮🇹
Policlinico Univesitario Gemelli, Roma, Italy
🇮🇹
Ospedale Cisanello, Pisa, Italy
🇮🇹
Policlinico Santa Maria alle Scotte, Siena, Italy

A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: CHF6001

First Posted Date: 2012-09-21

Last Posted Date: 2017-03-30

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 36

Registration Number: NCT01689571

Locations: 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
🇬🇧
Respiratory Clinical Trials, London, United Kingdom
🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

Phase 3

Withdrawn

Conditions: Asthma in Children

Interventions: Drug: combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
Drug: free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg

First Posted Date: 2012-08-07

Last Posted Date: 2018-06-18

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Registration Number: NCT01658891

Locations: 🇩🇰
BørneAstmaKlinikken, Copenhagen, Denmark

Retrospective Observational Study to Compare Cystic Fibrosis Patients in Two Decades Before and After 2000

Completed

Conditions: Cystic Fibrosis

First Posted Date: 2012-07-27

Last Posted Date: 2013-07-31

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 92

Registration Number: NCT01651455

Locations: 🇮🇹
U.O. Azienda Ospedaliera, Verona, Veneto, Italy

An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device

Phase 2

Completed

Conditions: Asthma

Interventions: Device: Inhalation through Chiesi NEXThaler DPI

First Posted Date: 2012-07-27

Last Posted Date: 2018-04-13

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 41

Registration Number: NCT01651650

Locations: 🇮🇹
Clinica Pneumologica, AOU di Parma, Parma, Italy

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy